RANDOMIZED PHASE II STUDY OF DOCETAXEL, ADIAMYCIN AND CYTOXAN

多西紫杉醇、阿霉素和环磷酰胺的随机 II 期研究

• 批准号: 7982070
• 负责人: GEORGE SOMLO
• 金额: $ 9.28万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7982070
• 关键词: Adjuvant; Adjuvant Chemotherapy; Biological Preservation; Breast; Breast Carcinoma; City of Hope Comprehensive Cancer Center; Clinical Research; Collaborations; Computer Retrieval of Information on Scientific Projects Database; Cyclophosphamide; DNA; ERBB2 gene; Funding; Future; Grant; In complete remission; Institution; Normal tissue morphology; Outcome; Patients; Phase II Clinical Trials; RNA; Randomized; Research; Research Personnel; Resources; Source; Staging; Translational Research; United States National Institutes of Health; chemotherapy; docetaxel; malignant breast neoplasm; multidisciplinary; prognostic indicator; protein profiling; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Neo-adjuvant chemotherapy may allow breast preservation and down staging in patients with primary breast cancer. Higher pathological complete response rates following neo-adjuvant chemotherapy may predict for prolonged survival. This study will attempt to define a less toxic and potentially more effective neo-adjuvant regiment in patients with both HER-2 positive and HER-2 negative Stage II-III breast carcinoma. This neo-adjuvant setting also allows for exploratory analysis of protein profiles, DNA and RNA profiles of the tumor and normal tissue prior to and subsequent to chemotherapy in order to identify predictive and prognostics indicators of outcomes and potential targets for future therapy. This project will represent multidisciplinary and translational research collaborations amongst the clinical and research entities of the City of Hope Comprehensive Cancer Center.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 原发性乳腺癌患者的新辅助化学疗法可以允许乳房保存和下班。新辅助化学疗法后，较高的病理完整反应率可能会预测长时间的存活率。 这项研究将尝试定义HER-2阳性和HER-2阴性II-III乳腺癌患者的毒性较小，可能更有效的新辅助团。 这种新辅助环境还可以在化学疗法之前及之后进行肿瘤和正常组织的蛋白质谱，DNA和RNA谱进行探索性分析，以鉴定预测性和预后指标的结果以及未来治疗的潜在靶标。该项目将代表希望市综合癌症中心的临床和研究实体之间的多学科和翻译研究合作。